For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

Panelists discuss how advanced practice providers (APPs) implement effective monitoring strategies for patients with chronic myeloid leukemia (CML), including regular check-ins after starting new ...

Educating patients on the “risks and benefits” of clinical trials is a part of the pipeline for better treatment options in myeloproliferative neoplasms (MPNs) in which nurses can engage, said a nurse ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical work with patients involved in trials.

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with ...

Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib. Adding daratumumab (Darzalex) to bortezomib ...